AMAG Pharmaceuticals was acquired by Covis Pharma in late 2020 for approximately $498 million in an all-cash transaction, resulting in the company being taken private and delisted from the Nasdaq stock exchange. Prior to its acquisition, AMAG faced mounting financial pressures, generic competition for key products, restructuring initiatives, and shareholder activism. Following the completion of the buyout, its operations, commercial portfolio, and pharmaceutical pipeline were fully integrated into Covis Pharma's global specialty therapeutics infrastructure, ending its independent corporate lifespan.